XTL Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio
XTL Biopharmaceuticals Ltd cash flow-to-debt ratio. XTL Biopharmaceuticals Ltd (XTLB) has a Cash Flow-to-Debt Ratio of -0.10x as of December 2017, meaning its operating cash flow of ILA-301.00K could theoretically repay 0% of its total liabilities (ILA2.97 Million) in one year. Check earnings quality score of XTL Biopharmaceuticals Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of XTL Biopharmaceuticals Ltd (2013–2024)
Cash flow-to-debt ratio of XTL Biopharmaceuticals Ltd from 2013 to 2024. Historical debt coverage capacity for XTL Biopharmaceuticals Ltd across 12 annual periods. Also explore XTL Biopharmaceuticals Ltd (XTLB) equity growth momentum to track the company's year-over-year net asset growth rate.
XTL Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio by Year (2013–2024)
XTL Biopharmaceuticals Ltd cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for XTL Biopharmaceuticals Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of XTL Biopharmaceuticals Ltd.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | ILA-1.62 Million | ILA3.12 Million | ▲ +84.9% |
| 2023 | -3.43x | ILA-707.00K | ILA206.00K | ▲ +28.8% |
| 2022 | -4.82x | ILA-901.00K | ILA187.00K | ▼ -490.2% |
| 2021 | -0.82x | ILA-1.05 Million | ILA1.28 Million | ▲ +75.6% |
| 2020 | -3.35x | ILA-850.00K | ILA254.00K | ▲ +14.5% |
| 2019 | -3.91x | ILA-908.00K | ILA232.00K | ▼ -21.3% |
| 2018 | -3.23x | ILA-816.00K | ILA253.00K | ▼ -750.6% |
| 2017 | -0.38x | ILA-1.12 Million | ILA2.97 Million | ▲ +92.8% |
| 2016 | -5.25x | ILA-1.73 Million | ILA330.00K | ▼ -23.0% |
| 2015 | -4.27x | ILA-1.86 Million | ILA436.00K | ▼ -66.8% |
| 2014 | -2.56x | ILA-2.47 Million | ILA965.00K | ▼ -26.0% |
| 2013 | -2.03x | ILA-2.50 Million | ILA1.23 Million | — |